InflaRx CEO Niels Riedemann, MD, discusses the issue that arose and cost them some of their data for their investigational therapy being studied for SARS-CoV-2-induced acute respiratory distress syndrome (ARDS).
Comments
Log in with your Bluesky account to leave a comment
Comments